| Literature DB >> 33235302 |
Abdoulaye Diane1, Naela Mahmoud1,2, Ilham Bensmail1, Namat Khattab1, Hanan A Abunada1, Mohammed Dehbi3,4.
Abstract
Persistent ER stress, mitochondrial dysfunction and failure of the heat shock response (HSR) are fundamental hallmarks of insulin resistance (IR); one of the early core metabolic aberrations that leads to type 2 diabetes (T2D). The antioxidant α-lipoic acid (ALA) has been shown to attenuate metabolic stress and improve insulin sensitivity in part through activation of the heat shock response (HSR). However, these studies have been focused on a subset of heat shock proteins (HSPs). In the current investigation, we assessed whether ALA has an effect on modulating the expression of DNAJB3/HSP40 cochaperone; a potential therapeutic target with a novel role in mitigating metabolic stress and promoting insulin signaling. Treatment of C2C12 cells with 0.3 mM of ALA triggers a significant increase in the expression of DNAJB3 mRNA and protein. A similar increase in DNAJB3 mRNA was also observed in HepG2 cells. We next investigated the significance of such activation on endoplasmic reticulum (ER) stress and glucose uptake. ALA pre-treatment significantly reduced the expression of ER stress markers namely, GRP78, XBP1, sXBP1 and ATF4 in response to tunicamycin. In functional assays, ALA treatment abrogated significantly the tunicamycin-mediated transcriptional activation of ATF6 while it enhanced the insulin-stimulated glucose uptake and Glut4 translocation. Silencing the expression of DNAJB3 but not HSP72 abolished the protective effect of ALA on tunicamycin-induced ER stress, suggesting thus that DNAJB3 is a key mediator of ALA-alleviated tunicamycin-induced ER stress. Furthermore, the effect of ALA on insulin-stimulated glucose uptake is significantly reduced in C2C12 and HepG2 cells transfected with DNAJB3 siRNA. In summary, our results are supportive of an essential role of DNAJB3 as a molecular target through which ALA alleviates ER stress and improves glucose uptake.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33235302 PMCID: PMC7687893 DOI: 10.1038/s41598-020-77621-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
List of siRNAs and sequences.
| Species/genes | Dharmacon references | Target sequence |
|---|---|---|
| Mouse/Dnajb3 | 1. A-046394-13 | CCGAAAUAAUUAAUGGCAA |
| 2. A-046394-14 | UUAAAGUCCCUGAUAAUUA | |
| 3. A-046394-15 | CAGGCAACUACAAGUCGGU | |
| 4. A-046394-16 | GGCUUCGCUUCGUUAGAUA | |
| Human/Dnajb3 | 1. A-032304-13 | CCUUUGACCUCUUGGGAAA |
| 2. A-032304-14 | CAUUUGACUUUAUUGUUUA | |
| 3. A-032304-15 | GCUGUACCCAAGAAUUUAU | |
| 4. A-032304-16 | CUGAAAUAGUUGAUGGUAA | |
| Mouse/HSP72 | 1. A-054644-13 | CCGCUGAUGUGAUUUGUUU |
| 2. A-054644-14 | UUAUCUUCCCUGUUAAUUA | |
| 3. A-054644-15 | CUGUCAUUAUUUCAAGUUU | |
| 4. A-054644-16 | CUUUCAGUUACUUUGUGUA | |
| Human/HSP72 | 1. A-005168-14 | CUAGUAUUUCUGUUUGUCA |
| 2. A-005168-15 | CUGCCAUCUUACGACUAUU | |
| 3. A-005168-17 | CCUGUGUUUGCAAUGUUGA | |
| 4. A-005168-18 | CCAUUGAGGAGGUAGAUUA | |
| Scrambled control | D-001910-10-05 | UGGUUUACAUGUCGACUAA |
| D-001910-10-05 | UGGUUUACAUGUUUUCUGA | |
| D-001910-10-05 | UGGUUUACAUGUUUUCCUA | |
| D-001910-10-05 | UGGUUUACAUGUUGUGUGA |
Primer list and sequences.
| Gene | Forward | Reverse |
|---|---|---|
| DNAJB3 | 5′-AGGGGCTGTACCCTTCTCTA-3′ | 5′-AGTTTCCTGGAGAACCGAAG-3′ |
| SOD1 | 5′-GAGAGGCATGTTGGAGACCT-3′ | 5′-CCACCTTTGCCCAAGTCATC-3′ |
| Catalase | 5′-AGGAGGCAGAAACTTTCCCA-3′ | 5′-GGCCCTGAAGCATTTTGTCA-3′ |
| GPX1 | 5′-ATCAGTTCGGACACCAGGAG-3′ | 5′-GATGTACTTGGGGTCGGTCA-3′ |
| ATF4 | 5′-GGGTTCTGTCTTCCACTCCA-3′ | 5′-AAGCAGCAGAGTCAGGCTTTC-3′ |
| GRP78 | 5′-AATTTCTGCCATGGTTCTCA-3′ | 5′-AGCATCTTTGGTTGCTTGTC-3′ |
| XBP1 | 5′-TCCCCAGAACATCTTCCCAT-3′ | 5′-ACATGACAGGGTCCAACTTG-3′ |
| sXPB1 | 5′-CTGAGTCCGAATCAGGTGCAG-3′ | 5′-GTCCATGGGAAGATGTTCTGG-3′ |
| HSF1 | 5′-GCTCAACATGTATGGCTTCC-3′ | 5′-GCTGGTCACTTTCCTCTTGA-3′ |
| HSP70 | 5′-TCTCCTGTCTTGTCCGAGAG-3′ | 5′-ATGCTGACTTGACCTTGAGC-3′ |
| HSP72 | 5′-GACAAGAAGAAGGTGCTGGA-3′ | 5′-TGGTACAGCCCACTGATGAT-3′ |
| HSP90 | 5′-TGAAACTGCTCTGCTCTCCT-3′ | 5′-CTCCTCTGCAGTGACCTCAT-3′ |
| PGC1α | 5′-CACCAAACCCACAGAAAACAG-3′ | 5′GGG TCAGAGGAAGAGATAAAGTTG-3′ |
| TFAM | 5′-GCTTGGAAAACCAAAAAGAC-3′ | 5′-CCCAAGACTTCATTTCATT-3′ |
| PPARγ | 5′-GATGTCTCACAATGCCATCAG-3′ | 5′-TCAGCAGACTCTGGGTTCAG-3′ |
| PPARα | 5′-AACATCGAGTGTCGAATATGTGG-3′ | 5′-CCGAATAGTTCGCCGAAAGAA-3′ |
| Cytochrome C | 5′-CTGTGGAAAAGGGAGGCAAG-3′ | 5′-CACCTGGTAATTCTGCACTGG-3′ |
| GAPDH | 5′-CTGGAGAAACCTGCCAAGTA-3′ | 5′-AGTGGGAGTTGCTGTTGAAG-3′ |
| Actin | 5′-AAGAGCTATGAGCTGCCTGA-3′ | 5′-GATGCCACAGGATTCCATAC-3′ |
Figure 1Alpha lipoic acid (ALA) induces the endogenous expression of DNAJB3 in C2C12 and HepG2 cells. (A) RT-PCR data showing the effect of 0.3 mM ALA for 24 h on the expression of representative components of the heat shock response in C2C12 cells. (B) Dose and time effects of ALA on the expression of DNAJB3 mRNA in C2C12 cells. Western blots confirming the positive effect of 24 h treatment with ALA on the expression of DNAJB3 (C) and HSP72 (D) proteins in C2C12 cells. Full-length blots are displayed in Supplementary Fig. S1. (E) ALA at 0.3 mM for 24 h also increases the expression of DNAJB3 mRNA in HepG2 cells. Ethanol was used at 0.25% as a vehicle. After performing Shapiro–Wilk normality test, t test was used to compare the difference between ALA and vehicle. NS not significant; *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 2ALA alleviates tunicamycin-induced ER stress. (A,B) Pre-treatment of C2C12 cells with 0.3 mM ALA abolishes significantly the mRNA expression of classical ER stress markers in response to tunicamycin treatment (A). (B) Western blot confirming the effect of ALA on tunicamycin-induced expression of GRP78 protein. Full-length blots are displayed in Supplementary Fig. S2. ALA also reduces ATF6-dependent luciferase activity in response to tunicamycin using a functional luciferase-based assay both in C2C12 (C) and HepG2 (D) cells. Ethanol and DMSO were used at 0.25% as vehicles for ALA and tunicamycin, respectively. After performing Shapiro–Wilk normality test, one way ANOVA was used to compare the effect of treatments. NS not significant; *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 3ALA improves mitochondrial function and the oxidative stress scavenging system. (A) ALA treatment triggers a significant increase in the expression of genes involved in mitochondrial biogenesis and function. (B) Representative images showing the effect of ALA treatment on enhancing the mitochondrial activity as revealed by MitoTracker (Red staining). Cells were counter screened with DAP (Blue staining). The images were acquired using a 25 ×/0.8 NA objective lens (LD LCI Plan‐Apochromat; Carl Zeiss Inc.,) mounted on a LSM (Zeiss LSM 780; Carl Zeiss Inc.). The fluorescence intensity (40 cells in the vehicle group and 41 cells in the ALA group) was quantified using ImageJ 1.52v software (NIH, Bethesda, MA, USA) and the fold change in fluorescence intensity was calculated and plotted. (C) ALA stimulates the endogenous mRNA expression of Catalase, Superoxide dismutase 1 (SOD1) and glutathione peroxidase 1 (GPX1) genes in response to 300 μM H2O2 treatment for 3 h. Ethanol was used at 0.25% as vehicles for ALA. After performing Shapiro–Wilk normality test, t test was used to compare the difference between ALA and vehicle (A) and one-way ANOVA was used to compare the effect of treatments (C). NS not significant; *P < 0.05, **P < 0.01. ***P < 0.001.
Figure 4Silencing the expression of DNAB3 abolishes the protective effect of ALA on tunicamycin-induced ER stress in C2C12 cells. (A,B) Knocking down the expression of DNAJB3 and HSP72 with 20 nM of specific siRNA blunted the endogenous expression of DNAJB3 and HSP72 mRNAs (A) and proteins (B). Actin was used as internal control for both RT-PCR and western blots. Full-length blots are displayed in Supplementary Fig. S4. ALA fails to protect siRNA DNAJB3-transfected C2C12 cells from tunicamycin-induced mRNA expression of ER stress markers (C) and ATF6-dependent luciferase activity (D). Ethanol and DMSO were used at 0.25% as vehicles for ALA and tunicamycin, respectively. After performing Shapiro–Wilk normality test, t test was used to compare the difference between ALA and vehicle (A) and two-ways ANOVA was used to compare the effect of treatments (B,C). NS not significant; *P < 0.05; **P < 0.01; ***P < 0.001; #P < 0.0001.
Figure 5Silencing the expression of DNAB3 abolishes the protective effect of ALA on tunicamycin-induced ER stress in HepG2 cells. (A) Knocking down the expression of DNAJB3 and HSP72 mRNA with 20 nM of specific siRNA reduced significantly the endogenous expression of DNAJB3 and HSP72 mRNA. Actin gene was used as a reference control. ALA fails to protect cells from tunicamycin-induced mRNA expression of ER stress markers (B) and ATF6-dependent luciferase activity (C) in cells transfected with siRNA specific for DNAJB3. Ethanol and DMSO were used at 0.25% as vehicles for ALA and tunicamycin, respectively. After performing Shapiro–Wilk normality test, t test was used to compare the difference between ALA and vehicle (A) and two-ways ANOVA was used to compare the effect of treatments (B,C). NS not significant; *P < 0.05; **P < 0.01; ***P < 0.001; #P < 0.0001.
Figure 6Silencing the expression of DNAB3 abrogated the effect of ALA on enhancing glucose uptake in C2C12 and HepG2 cells. (A) Effect of ALA on insulin-stimulated glucose uptake in C2C12 cells. (B,C) Silencing the expression of DNAJB3 abrogated the effect of ALA on insulin-stimulated glucose uptake as compared to scrambled siRNA control in C2C12 cells (B) and HepG2 cells (C). (D,E) Effect of ALA on insulin-mediated Glut4 translocation in C2C12 cells. After performing Shapiro–Wilk normality test, t test was used to compare the difference between ALA and vehicle (A,D) and one-ways ANOVA was used to test the DNAJB3 effect (B,C). Ethanol was used at 0.25% as vehicles for ALA. NS not significant; **P < 0.01; ***P < 0.001.